While cell-free DNA is our business, it’s patients who power our purpose

Steve Chapman is the chief executive officer of Natera, a global leader in cell-free DNA and genetic testing in oncology, women’s health, and organ health. He also serves on the company’s board of directors.

Chapman is a leading authority on the commercialization of genetic testing. Under his leadership, Natera has launched 20 products that have transformed patient care, including two of the fastest growing genetic tests of all time. The company’s suite of products includes the Signatera™ oncology test for molecular residual disease; the Prospera™ transplant assessment test; the Renasight™ kidney gene panel which screens for genetic causes of chronic kidney disease; and the highly differentiated Panorama™ test serving patients in the non-invasive prenatal testing market. 

Before his appointment as CEO in 2019, Chapman held a number of other leadership positions at Natera including chief operating officer. Earlier in his career, he worked at Genzyme Genetics. He began his career as a researcher in the department of human genetics at the University of California Los Angeles (UCLA), where he designed arrays identifying SNPs associated with multiple sclerosis. 

In 2024, Chapman was named “BioTechnology Innovator of the Year” by BioTech Breakthrough. He has been a guest on CNBC and other shows and podcasts to share more about Natera’s impact on patient care in the field of personalized genetic testing and diagnostics. 

Chapman is an author on multiple scientific papers. He graduated with honors and holds a B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA.

​

Mike Brophy is Natera’s CFO, he joined Natera in 2015 serving as Natera’s Senior Vice President of Finance and Investor Relations, and prior to that as Vice President of Corporate Development and Investor Relations. Prior to joining Natera, he served as an executive director and as a vice president in the investment banking division of Morgan Stanley, where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds a master’s degree in business administration from the University of California, Los Angeles, and a Bachelor of Science degree in economics from the United States Air Force Academy. His military career included leading a multi-agency, 10-person team on a $1.4 billion contract to modernize 10 remote satellite tracking stations worldwide.

Jerry Diffley joined Natera in August of 2017 as its Chief Compliance and Privacy Officer. Mr. Diffley is a seasoned laboratory executive with extensive experience in U.S. and international laboratory compliance, privacy, billing and laboratory operations.

Prior to joining Natera, Mr. Diffley worked at Quest Diagnostics for over 23 years in a variety of operational positions and more recently in its Legal Compliance function. Mr. Diffley holds a B.S. in Education from SUNY Plattsburgh and a Master’s degree in Business and Healthcare Administration from Stony Brook University.

Dr. Eric Evans joined Natera in 2020 as Chief Scientific Officer. Prior to joining Natera, he was co-founder and Chief Scientific Officer of Counsyl for 12 years. In that role, he led R&D and clinical operations for a molecular diagnostics portfolio in women’s health and oncology. He has authored papers in reproductive genetics and molecular diagnostics, including journals such as JAMA, Genetics in Medicine, Clinical Chemistry, and Prenatal Diagnosis. He received his B.S. in Biological Sciences from the University of Delaware and his Ph.D. in Genetics from Stanford University. While at Stanford, he was a Stanford Graduate Fellow working on the genetics of aging and the immune system.

Rishi Kacker serves as Natera’s Chief Technology Officer, bringing 20-years of experience in software, genetics, and health tech entrepreneurship. At Natera he is responsible for leading a team including product, UX, software engineering and IT with the mission to expand access to genetic testing for millions each year through innovations/transformation in the patient and provider experience. Additionally, the team has launched a massive clinico-genomic data and research platform being used to accelerate our knowledge of genetic disease. Prior to Natera, Mr. Kacker was the Chief Technology Officer at Myriad Genetics and co-founder and SVP of Technology at Counsyl (acquired by Myriad Genetics). He started his career as co-founder of Voltage Security, a data security and enterprise software business that was acquired by HP Enterprise. Mr. Kacker holds a B.S. degree in computer science from Stanford University.

As Senior Vice President of Laboratory Affairs & Quality, and Natera’s corporate CLIA Laboratory Director, Dr. Keen-Kim is responsible for the overall operation and administration of the clinical laboratories, as well as Natera’s Quality culture. Since joining Natera in 2018, Dr. Keen-Kim built the genetic variant classification and curation processes, has grown data analysis and clinical reporting operations 4-fold, and provides daily quality oversight and risk management in oncology, women’s health, and transplant diagnostics. With expertise in cell-free DNA, Next Generation Sequencing, and automation technologies, Dr. Keen-Kim earned a bachelor’s degree from Carnegie Mellon University, a Ph.D. from MIT, completed her fellowship at UCLA, and currently serves as an Adjunct Clinical Professor at Stanford University School of Medicine. She is licensed by California and New York to direct medical laboratories and maintains three HHS-approved board certifications. Dr. Keen-Kim is a mentor and champion for women leaders and is passionate about staff training and development to create growth opportunities for the next generation.

Chitra Kotwaliwale serves as senior vice president of clinical & commercial operations and portfolio management. She joined Natera in 2019 and has held multiple roles across product management and strategy, overseeing product management for the women’s health team, managing overall strategic planning and PMO for Engineering/R&D, and coordinating global product strategy. Prior to joining Natera, Chitra served as director of product marketing at Agilent Technologies, where she managed the company’s product management team responsible for target enrichment content products for rare diseases and oncology. She previously served as senior product manager of sequencing at Complete Genomics, and prior to that, as a computational biologist at Adaptive Biotechnologies (formerly Squenta, Inc.). Chitra holds a B.A. in biology from the College of Wooster and a Ph.D. in molecular and cell biology from the University of Washington and the Fred Hutchinson Cancer Center. She completed her postdoctoral fellowships at the University of California, Berkeley, which was funded by prestigious fellowships from the Damon Runyon Cancer Research Foundation and Howard Hughes Medical Institute.

Solomon Moshkevich serves as president, clinical diagnostics, where he oversees productization, clinical validation, commercialization, and quality across the company. Since joining Natera in 2011, Solomon has built and led multiple teams including global marketing, product management, medical and scientific affairs, commercial operations, clinical trial operations, business development, international sales, program management and portfolio strategy; and he has played a leading role in the development, clinical validation and commercial success of all Natera’s cell-free DNA products including Panorama, Prospera, and Signatera. Most recently, Solomon served as general manager of oncology for the company, overseeing a period of tremendous growth and leading the company’s efforts to achieve Medicare coverage for Signatera across multiple cancer types. Solomon began his career as a consultant with Bain & Company in New York before joining the private equity investment team at Parthenon Capital in Boston; and he currently serves on the Board of Directors for the Ronald McDonald House Charities of the Bay Area. He graduated from Columbia University summa cum laude with a B.A. in Economics and Mathematics, and he holds an M.B.A. from Stanford University.

Anu Pai leads Natera’s R&D Program Office. With more than 25 years of experience in product development and management, Anu joined Natera from Roche Diagnostics where she held various leadership roles in assay development, product and portfolio management, developing and launching PCR-based products for infectious diseases & blood screening, microbiology and cervical Cancer screening. Anu started her career as an R&D scientist working on multiplex PCR Assay for screening HIV, HCV and HBV, she has also managed large scale clinical trials, as well as design control and regulatory processes, having worked on IVD, RUO, IUO and Companion Diagnostics products. Anu holds an M.S in Chemistry from the University of Kentucky.

Sheetal Parmar serves as senior vice president of medical affairs for women’s health at Natera. She is a board-certified genetic counselor specializing in prenatal diagnosis and screening. Since joining Natera in 2013, Sheetal has held a number of positions, including senior director of clinical genetic services and director of medical education. Prior to Natera, she worked for 11 years as the lead prenatal genetic counselor at a high-risk prenatal diagnosis clinic and cytogenetic laboratory.

Sheetal serves on the Board of Directors for the National Society of Genetic Counselors (NSGC). In 2020, she accepted the Leading Women Entrepreneur Force for Change Illuminator award for her leadership and contributions to Natera’s positive impact on the lives of others during the COVID-19 pandemic.

Sheetal received her BA in Molecular and Cell Biology from UC Berkeley and her MS in Genetic Counseling from the University of Cincinnati, where she was an Albert C. Yates Scholar and Fellow.

Daniel Rabinowitz is Secretary and Chief Legal Officer of Natera. Prior to joining Natera, he was a corporate partner at the law firm McDermott, Will & Emery, and, before that, was also a corporate lawyer at the law firm Davis Polk & Wardwell. He has worked in the United States and Europe advising domestic, foreign, public, and private companies on capital raisings, M&A, investment management and compliance with US federal and state securities law. He has studied genetics, biochemistry, and molecular biology at Harvard University Extension School and attended courses on the legal and ethical aspects of biotechnology at Harvard Law School. Mr. Rabinowitz completed his B.A. and LL.B. degrees at the University of the Witwatersrand, South Africa, graduating at the top of his law school class, and completed his LL.M. at New York University School of Law with both Rotary Foundation and Fulbright Scholarships. Admitted in New York only.

Dr. Matthew Rabinowitz is co-founder of Natera and currently serves as the Executive Chairman of the board of directors. He served as Natera’s Chief Executive Officer from 2005 to 2019. He serves as a chairman, director or adviser to many companies and nonprofits involved in diagnostics, biotech, AI, health services and nature conservation and manages an early stage technology venture fund focused on biotech, security and AI. Companies he founded have twice received the World Economic Forum Technology Pioneer award, given in those years to 20 companies worldwide, and thrice received Edison Awards in the United States. He has served as consulting professor in Aeronautics and Astronautics at Stanford and visiting faculty in Genetics at Harvard and received the Scott Helt Award from IEEE. He has authored over 100 patents and publications respectively, including papers in the top reproductive, transplant and oncology journals, SCIENCE and Nature (cover). He has led the development of the highest volume clinical genetic test in US history, which transformed pregnancy management; a technology that tracks an individual patient’s tumor mutations in blood that has transformed cancer management with multiple FDA breakthrough designations; and the first whole genome polygenic modelling of embryos to prevent conferring disease risks to our children and other breakthrough products. He was named R&D Leader of the Year by R&D World in 2024. Dr Rabinowitz studied EE and Physics at Stanford, receiving the Levin and Terman awards, the top academic awards offered by each department, and a graduate fellowship to the school of engineering, where he completed a PhD in Electrical Engineering.

Dr. John Ryan joined Natera as its Chief Laboratory Officer in 2023. Dr. Ryan brings more than twenty eight years of operations experience, with expertise in diagnostic laboratory operations, laboratory partnerships, supply chain management, kit manufacturing and customer service. He most recently served as the Senior Vice President of Operations at Myriad Genetics, overseeing its Neuroscience, Women’s Health, Oncology and International Operations. Dr. Ryan previously served in various roles at Myriad Genetics including Vice President of Hereditary Cancer Operations, Senior Director of Customer Service and Senior Director of Operations. Prior to his time at Myriad Genetics, Dr. Ryan served in the Armed Forces DNA Identification Lab. He obtained a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Cruz, a Ph.D. in Genetics from Stony Brook University and an Executive MBA from the University of Utah David Eccles School of Business.

Robert Schueren is an accomplished industry veteran with extensive molecular diagnostics, genomics, and pharma experience. Mr. Schueren has enjoyed an expansive 30-year career and has been a driving force behind rapid business growth at both start-up and large biotech companies. Most recently, he was CEO of IntegenX Inc., playing a critical role in the growth and success of the company, and ultimate acquisition by Thermo Fisher Scientific, as well as successfully leading a lobbying effort to pass the Rapid DNA Act of 2017. Mr. Schueren previously held executive leadership roles including GM of Genomics at Agilent Technologies, Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc. He formerly held leadership and commercial roles at Arcturus Bioscience, Accumetrics, Biosite Diagnostics, Gen-Probe, and Abbott Labs. Mr. Schueren received a BS in Pharmacy from Temple University.

Bernie Tobin is responsible for strategy and execution for Natera’s organ health products. Mr. Tobin is a 25-year veteran of the healthcare industry with his most recent role serving as President of Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics. Crescendo focused on using proteomics to deliver precision medicine to patients with autoimmune disorders.

Previously, Mr. Tobin held several senior-level positions at Amgen including General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. In addition, he led the global integration of a business development acquisition in over 100 countries. Prior to that, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co.  He received his B.S. degree in Public Service and Administration from Iowa State University and his M.B.A. from the Fuqua School of Business, Duke University.